Abstract
Interest for extracellular nucleotides has increased since the pioneer work of Burnstock in the early seventies. Research on cellular functions modulated by purines and pyrimidines has led to the identification and characterization of the different components of purine signaling, namely purinoceptors and ecto-nucleotidases. Receptors for tri- and diphosphonucleosides, known as P2 nucleotide receptors, are designated either P2Y receptors, for those coupled to Gproteins, or P2X for those which are ligand gated-ion channels. Ecto-nucleoside triphosphate diphosphohydrolase (NTPDase; EC 3.6.1.5), previously identified as ecto-ATPase, ecto-ATPDase or CD39, is now considered as the main ecto-nucleotidase responsible for the sequential hydrolysis of beta and gamma phosphates of tri- and diphosphonucleosides. More recently, research has been focused on the development of specific agonists and antagonists to P2 purinoceptors. The need to develop specific inhibitors for NTPDase to understand the role of this enzyme has clearly emerged. This paper covers the development of specific molecules targeting purinergic signaling, more specifically the inhibition of NTPDase and their impact on the different physiological systems.
Current Drug Targets
Title: Purine Signaling and Potential New Therapeutic Approach: Possible Outcomes of NTPDase Inhibition
Volume: 3 Issue: 3
Author(s): F.P. Gendron, O. Benrezzak, B.W. Krugh, Q. Kong, G.A. Weisman and A.R. Beaudoin
Affiliation:
Abstract: Interest for extracellular nucleotides has increased since the pioneer work of Burnstock in the early seventies. Research on cellular functions modulated by purines and pyrimidines has led to the identification and characterization of the different components of purine signaling, namely purinoceptors and ecto-nucleotidases. Receptors for tri- and diphosphonucleosides, known as P2 nucleotide receptors, are designated either P2Y receptors, for those coupled to Gproteins, or P2X for those which are ligand gated-ion channels. Ecto-nucleoside triphosphate diphosphohydrolase (NTPDase; EC 3.6.1.5), previously identified as ecto-ATPase, ecto-ATPDase or CD39, is now considered as the main ecto-nucleotidase responsible for the sequential hydrolysis of beta and gamma phosphates of tri- and diphosphonucleosides. More recently, research has been focused on the development of specific agonists and antagonists to P2 purinoceptors. The need to develop specific inhibitors for NTPDase to understand the role of this enzyme has clearly emerged. This paper covers the development of specific molecules targeting purinergic signaling, more specifically the inhibition of NTPDase and their impact on the different physiological systems.
Export Options
About this article
Cite this article as:
F.P. Gendron , O. Benrezzak , B.W. Krugh , Q. Kong , G.A. Weisman and A.R. Beaudoin , Purine Signaling and Potential New Therapeutic Approach: Possible Outcomes of NTPDase Inhibition, Current Drug Targets 2002; 3 (3) . https://dx.doi.org/10.2174/1389450023347713
DOI https://dx.doi.org/10.2174/1389450023347713 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
LNA Antisense: A Review
Current Physical Chemistry Phospholipid Nanosomes
Current Drug Delivery Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Current Drug Targets Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Current Cancer Therapy Reviews CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Transcriptome Analysis of mRNA in Uterine Leiomyoma Using Next-generation RNA Sequencing
Anti-Cancer Agents in Medicinal Chemistry mRNA as a Therapeutic Target in Lung Disease
Drug Design Reviews - Online (Discontinued) Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antiproliferative Activity of 2-arylidene 6-(2-aryl-2-oxoethoxy)Benzofuran-3-one Derivatives
Letters in Drug Design & Discovery The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Oligonucleotides and Oligonucleotide Conjugates: A New Approach for Cancer Treatment
Current Medicinal Chemistry Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design AFM Applications to the Analysis of Plasma-Treated Surface Growth and Nanocomposite Materials
Current Nanoscience